Labcorp Holdings Inc. $LH Stock Position Lowered by Resources Management Corp CT ADV

Posted by Brian Himes on Jun 16th, 2026

Resources Management Corp CT ADV lessened its position in Labcorp Holdings Inc. (NYSE:LH – Free Report) by 93.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 770 shares of the medical research company’s stock after selling 11,675 shares during the quarter. Resources Management Corp CT ADV’s holdings in Labcorp were worth $193,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. JPL Wealth Management LLC acquired a new stake in shares of Labcorp during the third quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Labcorp during the fourth quarter worth $26,000. Hilton Head Capital Partners LLC acquired a new stake in shares of Labcorp during the fourth quarter worth $27,000. Eagle Bay Advisors LLC acquired a new stake in shares of Labcorp during the fourth quarter worth $29,000. Finally, Headlands Technologies LLC raised its position in shares of Labcorp by 300.0% during the second quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock worth $34,000 after purchasing an additional 96 shares during the period. Institutional investors own 95.94% of the company’s stock.

Insider Activity

In other Labcorp news, CEO Adam H. Schechter sold 5,903 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the transaction, the chief executive officer directly owned 107,234 shares of the company’s stock, valued at $27,291,053. This represents a 5.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn W. Kyle sold 762 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $263.89, for a total value of $201,084.18. Following the completion of the transaction, the executive vice president directly owned 3,813 shares in the company, valued at approximately $1,006,212.57. The trade was a 16.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.84% of the company’s stock.

Analyst Upgrades and Downgrades

LH has been the topic of a number of recent analyst reports. Wall Street Zen lowered Labcorp from a “buy” rating to a “hold” rating in a research report on Saturday. Robert W. Baird set a $334.00 target price on Labcorp in a research report on Friday, May 1st. Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Labcorp in a research report on Wednesday, April 8th. Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a research report on Tuesday, February 17th. Finally, Piper Sandler boosted their target price on Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 24th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $308.00.

Get Our Latest Analysis on Labcorp

Labcorp Stock Down 0.6%

NYSE:LH opened at $264.61 on Tuesday. The firm has a market capitalization of $21.70 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 1.86 and a beta of 0.90. Labcorp Holdings Inc. has a 1-year low of $241.81 and a 1-year high of $293.72. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68. The business’s fifty day moving average price is $262.46 and its 200 day moving average price is $265.74.

Labcorp (NYSE:LH – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.09 by $0.16. The firm had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.Labcorp’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, sell-side analysts forecast that Labcorp Holdings Inc. will post 18 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 11th. Shareholders of record on Friday, May 29th were given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend was Friday, May 29th. Labcorp’s dividend payout ratio is presently 25.51%.

Labcorp Profile

(Free Report)

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.